Galmed Pharmaceuticals (GLMD) Liabilities and Shareholders Equity (2013 - 2025)

Galmed Pharmaceuticals' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $18.6 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 0.69% year-over-year to $18.6 million; the TTM figure through Dec 2025 stood at $81.8 million (up 21.58% YoY), while the FY2025 annual figure was $18.6 million, up 0.69% from the prior year.
• Liabilities and Shareholders Equity was $18.6 million for Q4 2025 at Galmed Pharmaceuticals, down from $21.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $60.4 million in Q1 2021 to a low of $1.2 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $24.1 million across 5 years, with a median of $19.8 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity sank 96.05% in 2023, then surged 1116.16% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $36.6 million in 2021, then plunged by 54.76% to $16.6 million in 2022, then gained by 0.41% to $16.6 million in 2023, then gained by 11.25% to $18.5 million in 2024, then advanced by 0.69% to $18.6 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $18.6 million (Q4 2025), $21.6 million (Q3 2025), and $22.9 million (Q2 2025), per Business Quant data.